PR Newswire
LAS VEGAS, Jan. 28, 2026
The DUB inhibitors market is poised for steady growth, driven by rising interest in targeted protein degradation and novel oncology therapeutics. The growing prevalence of cancer and neurodegenerative disorders further supports market expansion. Additionally, the launch of emerging therapies such as ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), and others will propel the market.
LAS VEGAS, Jan. 28, 2026 /PRNewswire/ — DelveInsight’s DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Heart Failure, Parkinson’s Disease, Alzheimer’s Disease, Lymphoma, Breast Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DUB inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into leading markets (the US, EU4, UK, and Japan).
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Key Takeaways from the DUB Inhibitors Market Report
- The total market size of DUB inhibitors in the leading markets is expected to surge significantly by 2040.
- In 2024, the United States holds the largest share of the DUB inhibitors market among the 7MM.
- The report provides the total potential number of patients in the indications, such as Heart Failure, Parkinson’s Disease, Alzheimer’s Disease, Lymphoma, Breast Cancer, and others.
- Neurodegenerative diseases, including Parkinson’s and Alzheimer’s, will become the second leading cause of death worldwide by 2040, surpassing deaths related to cancer.
- Leading DUB inhibitors companies, such as InSilico Medicine, Molecure, KSQ Therapeutics, Roche, Mission Therapeutics, Cothera Bioscience, Asieris Pharmaceuticals, Tango Therapeutics, and others, are developing novel DUB inhibitors that can be available in the DUB inhibitors market in the coming years.
- Some of the key DUB inhibitors in clinical trials include ISM-3091, OAT-4828, KSQ-4279, MTX652, MTX325, sepantronium bromide/PC-002/YM155, ASN-3186/AT-012, TNG348, and others.
Discover what is the global DUB inhibitors market size and forecast through 2040 @ https://www.delveinsight.com/sample-request/dub-inhibitors-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the DUB Inhibitors Market
- Rising Prevalence of Neurodegenerative Diseases: The prevalence of neurodegenerative diseases is rising steadily worldwide, driven by aging populations and longer life expectancy. Disorders such as Alzheimer’s, Parkinson’s, and others are placing a growing burden on healthcare systems and caregivers. Improved diagnostics are also identifying cases earlier and more accurately, contributing to higher reported prevalence.
- Broad Therapeutic Applications of DUB Inhibitors: DUB inhibitors are applicable across a wide range of diseases, including cancer, viral infections, and neurodegenerative disorders, due to their role in protein homeostasis.
- Promising DUB Inhibitor Assets Shaping the Future: Some of the potential drugs in the pipeline include ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), sepantronium bromide/PC-002/YM155 (Cothera Bioscience), ASN-3186/AT-012 (Asieris Pharmaceuticals), TNG348 (Tango Therapeutics), and others.
DUB Inhibitors Market Analysis
- Earlier DUB inhibitors rarely underwent detailed structure-activity relationship (SAR) studies, but more recent candidates have benefited from medicinal chemistry optimization, often guided by structural data.
- Current research efforts are focused on developing inhibitors targeting USP14, USP2, USP7, USP25/28, USP30, CSN5, STAMBP, and Rpn11, with increasing interest in JAMM-targeting drugs and multiple patents filed since 2014.
- Many DUBs are upregulated in cancer and contribute to tumor progression and drug resistance, positioning DUB inhibition as a promising therapeutic strategy.
- DUB inhibitors targeting USP1, USP7, USP14, and UCHL1 are being explored for their roles in suppressing tumor proliferation and overcoming immune evasion.
- USP11, MINDY1, and USP36 promote ERα stability and are associated with therapy resistance, whereas OTUB1 and OTUD1 function as tumor suppressors by limiting cell proliferation and metastasis.
- Targeting oncogenic and tumor-suppressive DUBs represents a novel opportunity for advancing breast cancer treatment strategies.
- DUBs such as USP14 and UCHL1 play critical roles in neuronal protein homeostasis, making them attractive targets for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s disease.
- Clinical development of DUB inhibitors is accelerating as the ubiquitin-proteasome system gains recognition as a central regulator of protein homeostasis and a viable therapeutic target.
- As of 2026, the DUB inhibitor landscape is in an early-to-mid stage of development, with most programs in preclinical, Phase I, or Phase II trials, yet the long-term therapeutic potential remains significant.
Learn more about future growth outlook and key trends in DUB inhibitors market @ DUB Inhibitors Analysis
DUB Inhibitors Competitive Landscape
The emerging drug pipeline for DUB inhibitors is diverse and includes several promising candidates, such as ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), sepantronium bromide/PC-002/YM155 (Cothera Bioscience), and others.
Mission Therapeutics’ MTX652 is a potent, highly selective investigational therapy currently in Phase II development that aims to restore mitochondrial quality and performance by stimulating mitophagy. It achieves this by inhibiting USP30, a mitochondria-localized deubiquitylating enzyme that suppresses mitophagy. By enhancing the removal of damaged mitochondria, MTX652 supports cellular health and resilience. The compound has demonstrated potential to mitigate mitochondrial dysfunction associated with ischemia-reperfusion injury (IRI) in cardiac and renal tissues following heart surgery. In addition, MTX652 may be expanded into Duchenne muscular dystrophy, where it could offer meaningful benefits for cardiomyopathy.
Cothera’s lead candidate, PC-002 (also known as YM155 or sepantronium bromide), is a Phase II, first-in-class small-molecule inhibitor targeting deubiquitylating enzymes (DUBs), which regulate protein stability by removing ubiquitin from proteins marked for degradation. Given that over half of human cancers exhibit elevated Myc expression, one of the most critical yet historically «undruggable» oncogenic drivers, PC-002 is designed to inhibit the DUB that stabilizes Myc in cancer cells. This results in selective Myc degradation and apoptosis induction in Myc-dependent tumors, positioning PC-002 as a potential therapeutic across multiple Myc-driven cancer indications.
KSQ Therapeutics/Roche’s KSQ-4279 is a first-in-class small-molecule inhibitor of USP1, a key regulator of the DNA damage response (DDR). Identified through KSQ’s proprietary CRISPRomics discovery platform, USP1 plays a distinct and well-defined role in DNA repair pathways that differ from those targeted by PARP inhibitors and other DDR-focused therapies currently in clinical development. KSQ-4279 is being evaluated in a Phase I/II clinical study (NCT06237881) involving patients with selected advanced solid tumors, featuring both dose-escalation and expansion cohorts as monotherapy and in combination regimens.
The anticipated launch of these emerging therapies are poised to transform the DUB inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DUB inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about who are the leading companies developing DUB inhibitors, visit @ DUB Inhibitors Treatment
What are DUB Inhibitors?
Deubiquitinase (DUB) inhibitors are a class of therapeutic agents designed to block the activity of deubiquitinases, enzymes that remove ubiquitin tags from proteins. In normal cells, DUBs help regulate protein stability, degradation, DNA repair, cell-cycle control, and signaling pathways by fine-tuning the ubiquitin-proteasome system. In many diseases, especially cancer, aberrant DUB activity stabilizes oncogenic proteins and dysregulates cellular processes. By inhibiting DUBs, these agents promote the accumulation of ubiquitinated proteins, restore controlled protein degradation, and can trigger cell-cycle arrest or apoptosis in diseased cells. As a result, DUB inhibitors are emerging as a promising therapeutic strategy in oncology and other areas where protein homeostasis is disrupted.
DUB Inhibitors Epidemiology Segmentation
The DUB inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020-2040 across the leading markets. The DUB inhibitors target patient pool is segmented into:
- Total Cases of Selected Indications for DUB Inhibitors
- Total Eligible Patient Pool for DUB Inhibitors in Selected Indications
- Total Treated Cases in Selected Indications for DUB Inhibitors
DUB Inhibitors Report Metrics
Details
Study Period
2020-2040
DUB Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
Heart Failure, Parkinson’s Disease, Alzheimer’s Disease, Lymphoma, Breast Cancer, and others
DUB Inhibitors Target Patient Pool Segmentation Total Cases of Selected Indications for DUB Inhibitors, Total Eligible Patient Pool for DUB
Inhibitors in Selected Indications, and Total Treated Cases in Selected Indications for DUB
Inhibitors
Key DUB Inhibitors Companies InSilico Medicine, Molecure, KSQ Therapeutics, Roche, Mission Therapeutics, Cothera Bioscience,
Asieris Pharmaceuticals, Tango Therapeutics, and others
Key DUB Inhibitors ISM-3091, OAT-4828, KSQ-4279, MTX652, MTX325, sepantronium bromide/PC-002/YM155, ASN-3186/AT-
012, TNG348, and others
Scope of the
DUB Inhibitors
Market Report
- DUB Inhibitors Therapeutic Assessment: DUB Inhibitors’ current marketed and emerging therapies
- DUB Inhibitors Market Dynamics: Conjoint Analysis of Emerging DUB Inhibitors Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, DUB Inhibitors Market Access and Reimbursement
Discover what drugs are in the DUB inhibitor pipeline @ DUB Inhibitors Clinical Trials
Table of Contents
1
DUB Inhibitors Market Key Insights
2
DUB Inhibitors Market Report Introduction
3
Key Highlights
4
Executive Summary
5
Key Events
6
Epidemiology and Market Forecast Methodology
7
DUB Inhibitors Market Overview at a Glance in the 7MM
7.1 Emerging Landscape (Analysis by Molecule Type, Phase, and Route of
Administration [RoA])
7.2
Market Share (%) Distribution by Therapies in 2040
7.3
Market Share (%) Distribution by Indications in 2040
8
Background and Overview
8.1
Introduction
8.2
Treatment
9
Target DUB Inhibitors Patient Pool
9.1
Key Findings
9.2
Assumptions and Rationale: 7MM
9.3
Epidemiology Scenario in the 7MM
9.3.1 Total Cases in Selected Indications for DUB Inhibitors in the 7MM
9.3.2 Total Eligible Patient Pool for DUB Inhibitors in Selected Indications in
the 7MM
9.3.3 Total Treated Cases in Selected Indications for DUB Inhibitors in the 7MM
10
Emerging DUB Inhibitors
10.1
Key Competitors
10.2
MTX652: Mission Therapeutics
10.2.1
Product description
10.2.2
Other developmental activity
10.2.3
Clinical developmental activities
10.2.3.1
Clinical trial information
10.2.4
Safety and efficacy
10.2.5
Analyst Views
10.3
Sepantronium Bromide (PC-002): Cothera Bioscience
10.4
KSQ-4279: KSQ Therapeutics
*List to be continued in the full report
11
DUB Inhibitors Market: 7MM analysis
11.1
Key Findings
11.2
DUB Inhibitors Market Outlook
11.3
Key DUB Inhibitors Market Forecast Assumptions
11.4
Total Market Size of DUB Inhibitors in the 7MM
11.5
United States DUB Inhibitors Market Size
11.5.1
DUB Inhibitors Market Size by Indications in the US
11.5.2
DUB Inhibitors Market Size by Therapies in the US
11.6
EU4 and the UK DUB Inhibitors Market Size
11.7
Japan DUB Inhibitors Market Size
12
DUB Inhibitors Market Unmet Needs
13
DUB Inhibitors Market SWOT Analysis
14
KOL Views on DUB Inhibitors
15
DUB Inhibitors Market Access and Reimbursement
15.1
United States
15.2
EU4 and the UK
15.3
Japan
15.4 Summary and Comparison of Market Access and Pricing Policy Developments in
2025
15.5
Market Access and Reimbursement of DUB Inhibitors
16
Bibliography
17
DUB Inhibitors Market Report Methodology
Related Reports
Parkinson’s Disease Market
Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, and others.
Alzheimer’s Disease Market
Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, Alpha Cognition, Biogen, Otsuka Pharmaceutical, Lundbeck, and others.
Congestive Heart Failure Market
Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CHF companies, including Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others.
Breast Cancer Market
Breast Cancer Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected] +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/dub-inhibitors-market-to-witness-strong-expansion-across-7mm-by-2040-driven-by-the-launch-of-novel-therapeutics–delveinsight-302672095.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…